New Oral Anticoagulants: General Features and Review of Pivotal Clinical Trials
For the last half century, vitamin K antagonists (VKAs) have been used for treatment and prevention of venous thromboembolism and stroke prevention in patients with atrial fibrillation. However, their fragile pharmacokinetics, need for routine laboratory monitoring and dose adjustments complicated t...
Saved in:
| Main Author: | |
|---|---|
| Format: | Book |
| Published: |
Yong Chan Lee,
2016-12-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_2b49d9467d6c4aa1bbb22e2f1af5cf2a | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Sung-Won Jang |e author |
| 245 | 0 | 0 | |a New Oral Anticoagulants: General Features and Review of Pivotal Clinical Trials |
| 260 | |b Yong Chan Lee, |c 2016-12-01T00:00:00Z. | ||
| 500 | |a 1738-3331 | ||
| 500 | |a 10.7704/kjhugr.2016.16.4.178 | ||
| 520 | |a For the last half century, vitamin K antagonists (VKAs) have been used for treatment and prevention of venous thromboembolism and stroke prevention in patients with atrial fibrillation. However, their fragile pharmacokinetics, need for routine laboratory monitoring and dose adjustments complicated the use of these drugs. Recently, new oral anticoagulants (NOACs) have overcome the limitation of VKA therapy and shows favorable outcomes and better safety, especially for patients with intracranial hemorrhage, both in phase III clinical trials and real-world registry. Currently available NOACs are one thrombin inhibitor, dabigatran, and three Xa inhibitors, rivaroxaban, apixaban, and edoxaban. This review covers the pharmacokinetics, published pivotal clinical trials, and dose adjustments in chronic kidney disease. The reimbursement criteria, discontinuation during elective surgical procedure, issues on reversal agents are also discussed. | ||
| 546 | |a EN | ||
| 546 | |a KO | ||
| 690 | |a Thrombin | ||
| 690 | |a Factor Xa | ||
| 690 | |a Anticoagulants | ||
| 690 | |a Atrial fibrillation | ||
| 690 | |a Venous thromboembolism | ||
| 690 | |a Internal medicine | ||
| 690 | |a RC31-1245 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n The Korean Journal of Helicobacter and Upper Gastrointestinal Research, Vol 16, Iss 4, Pp 178-184 (2016) | |
| 787 | 0 | |n http://www.helicojournal.org/journal/view.html?doi=10.7704/kjhugr.2016.16.4.178 | |
| 787 | 0 | |n https://doaj.org/toc/1738-3331 | |
| 856 | 4 | 1 | |u https://doaj.org/article/2b49d9467d6c4aa1bbb22e2f1af5cf2a |z Connect to this object online. |